Sage Therapeutics
215 First Street
Cambridge
MA
02142
United States
Tel: 617-299-8380
Website: https://www.sagerx.com/
About Sage Therapeutics
Welcome To The Workplace With A Difference
Our vision is to fearlessly lead the way to create a world with better brain health – a vision we can only achieve with the help of our amazing team of highly knowledgeable, deeply passionate individuals.
At Sage, we believe that life is more than just a destination. We’re concerned with the journey, and we care deeply about everyone contributing to and benefiting from our own company journey. This means helping people discover the right path for them and carefully guiding colleagues along the way.
Stock Symbol:
SAGE
Fly-through video of our Cambridge Office. Feel what it's like to be on site.
402 articles about Sage Therapeutics
-
SAGE Therapeutics Announces Completion Of Enrollment For Phase 2 Proof-Of-Concept Trial Of SAGE-547 In Severe Postpartum Depression
5/27/2016
-
SAGE Therapeutics Announces First Quarter 2016 Financial Results
5/6/2016
-
SAGE Therapeutics To Report First Quarter 2016 Financial Results On Thursday, May 5, 2016
4/29/2016
-
SAGE Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting
4/18/2016
-
SAGE Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy of Neurology Annual Meeting
4/18/2016
-
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015
3/24/2016
-
SAGE Therapeutics Tanks as Hedge Fund Kerrisdale Capital Bets Lead Drug Will Fail Phase III Study
3/23/2016
-
SAGE Therapeutics Announces Proposed Public Offering Of Common Stock.
1/6/2016
-
Christmas Comes Early to SAGE Therapeutics Investors as Company Accelerates Promising Pipeline Timeline
12/17/2015
-
Decibel Therapeutics Appoints Jeff Jonas, M.D., CEO Of SAGE Therapeutics, To Its Board Of Directors
12/16/2015
-
SAGE Therapeutics To Present Three Poster Presentations At The American Epilepsy Society 69th Annual Meeting
12/2/2015
-
SAGE Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference
11/25/2015
-
Ligand Expands Captisol License And Supply Agreements With SAGE Therapeutics To Include SAGE-689
9/29/2015
-
SAGE Therapeutics To Participate In The 4th Annual Leerink Partners Rare Disease Roundtable
9/23/2015
-
SAGE Therapeutics Expands Leadership Team With Key Appointments
9/21/2015
-
SAGE Therapeutics Committs to Fighting Tremors After Lead Drug Shines in Small Study
9/3/2015
-
SAGE Therapeutics Announces First Patient Treated In Phase III STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus
8/17/2015
-
SAGE Therapeutics Announces Second Quarter 2015 Financial Results And Highlights Recent Progress
8/12/2015
-
SAGE Therapeutics Receives Special Protocol Assessment For Phase III STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus
8/6/2015
-
SAGE Therapeutics To Present At The Canaccord Genuity 35th Annual Growth Conference
8/5/2015